NanoViricides, Inc. (NNVC)

1.2400 -0.0700 (-5.34%) At close: 04:00PM EDT

NanoViricides, Inc.

1 Controls Drive
Shelton, CT 06484
United States
203 937 6137
https://www.nanoviricides.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 17

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Anil R. Diwan Ph.D.	Exec. Chairman, Pres, CEO & Sec.	400k	N/A	1959
Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA	Chief Financial Officer	129.6k	N/A	1959
Dr. Randall W. Barton Ph.D.	Chief Scientific Officer & Chief Regulatory Officer	N/A	N/A	1947

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.

Corporate Governance

NanoViricides, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.